A new Doppler signal enhancing agent for flow assessment in breast lesions.
OBJECTIVE
To determine the diagnostic performance of SonoVue (Bracco) in the enhancement of Doppler signals in breast lesions and in the improvement of diagnostic accuracy.


METHODS
This multicenter study included 220 patients undergoing investigations of parenchymal lesions, 40 of which had breast tumors. After a baseline Doppler examination, intravenous doses of 0.3, 0.6, 1.2 and 2.4 ml SonoVue were injected. Doppler signal quality before and after injection was compared. Off-site assessment of the global quality of Doppler signal and duration of clinical useful enhancement, as well as off-site and on-site evaluation of quality of color and spectral Doppler, were performed. On-site evaluation of diagnostic accuracy was also carried out. Safety assessments included monitoring of adverse events up to 24 h following the last injection of SonoVue.


RESULTS
On-site evaluations: baseline Doppler was conclusive in only 4/21 carcinomas and in 2/17 benign lesions. Enhanced Doppler improved differential diagnosis in 20/21 carcinomas and in 9/12 benign lesions. Time to color enhancement was 0.55 min for the lowest and 0.35 min for the highest dose. The total duration of enhancement was 3.47 min for the lowest and 5.62 min for the highest dose, respectively. Off-site assessment: SonoVue improved the quality of Doppler blood flow information both in parenchymal and focal lesions. Statistically significant changes from baseline in global quality of Doppler investigations were observed at all four SonoVue doses (P<0.05). The duration of clinically useful signal enhancement increased with doses and a significant dose relationship was obtained (P<0.001). Mild adverse events were observed in two patients only.


CONCLUSIONS
The results obtained from this study, following both off-site and on-site assessment, demonstrate that the administration of SonoVue to patients with focal breast lesions provides significant improvement over the baseline of Doppler signal quality and a clinically useful duration of signal enhancement, related to the dose. SonoVue was shown to be a safe and well-tolerated compound.
Madjar
H
H
Deutsche Klinik für Diagnostik (DKD), Aukammallee 33, 65191, Wiesbaden, Germany. gyn.madjar@dkd-wiesbaden.de
Prömpeler
H J
HJ
Del Favero
C
C
Hackelöer
B J
BJ
Llull
J B
JB
D000328:Adult; D001943:Breast Neoplasms / Q000098:blood supply / Q000000981:diagnostic imaging*; D003287:Contrast Media / Q000008:administration & dosage*; D018592:Cross-Over Studies; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008875:Middle Aged; D010743:Phospholipids; D012039:Regional Blood Flow; D013459:Sulfur Hexafluoride / Q000008:administration & dosage*; D018608:Ultrasonography, Doppler; D016217:Ultrasonography, Mammary; D014743:Videotape Recording
D003287:Contrast Media; D010743:Phospholipids; C420843:contrast agent BR1; D013459:Sulfur Hexafluoride